Key Highlights

  • Revenue of USD 19.0 million rose 35% and topped the USD 18.3 million estimate; loss per share was USD 0.06.
  • The company shipped more than 300 devices, a record, bringing its installed base to roughly 4,400 devices.
  • Full-year Revenue guidance now spans USD 68.5 million to USD 70 million, with the low end raised.
  • Adjusted EBITDA loss was USD 1.7 million, and the full-year loss is projected in the mid-single-digit millions.

908 Devices (NASDAQ:MASS) reported third quarter 2026 revenue of USD 19.0 million, up 35% from USD 14 million a year earlier and above the USD 18.3 million estimate. Loss per share was USD 0.06, against an estimated loss of USD 0.15. Handheld product and service revenue was USD 17.8 million, up 35%, while OEM and funded Partnership revenue was USD 1.1 million, up 42%.

The company shipped more than 300 devices in the quarter, a company record, including more than 200 FTIR devices and about two-thirds of a USD 6 million ProtectIR order from an Asia Pacific corrections agency. FTIR products made up 55% of third quarter revenue. Over nine months, FTIR was 49% of revenue, mass spectrometry 47% and NIRLab 4%. International customers represented 40% of third quarter revenue, double the prior-year share.

Connected Services and Product Pipeline

Management emphasized recurring revenue, which was USD 5.1 million in the quarter, up USD 0.2 million. For the nine months, Recurring Revenue was 29% of total revenue, compared with 36% a year earlier, as device sales rose to 71% of revenue from 64%. The company sold roughly 100 NIRLab devices in the quarter, and the narcotics platform passed 1 million cumulative scans, with daily scan Volume averaging about one per minute, up 74%.

The company announced a framework agreement worth more than USD 2 million with a defense customer replacing legacy equipment. Management said a next-generation MX908 is a meaningful growth driver for 2027 and could prompt device refreshes across an installed base of more than 3,000 MX908 units. It also described a testing result in a defense program as a constructive signal for potential commercial-off-the-shelf orders in 2027.

Guidance and Balance Sheet

Full-year 2026 revenue guidance now spans USD 68.5 million to USD 70 million. Management said it is on course to reduce the full-year adjusted EBITDA loss to the mid-single-digit millions, roughly one-third lower than in 2025 and inclusive of NIRLab. Third quarter adjusted EBITDA loss was USD 1.7 million.

The quarterly filing reports revenue from continuing operations of USD 48.4 million for the nine months, against USD 38.8 million a year earlier, and a net loss from continuing operations of USD 28.4 million, compared with USD 37.7 million. The accumulated Deficit was USD 251.7 million. The company stated that it believes existing cash, marketable securities and revenue are sufficient to fund operations for at least the next 12 months, and that it does not expect tariffs to materially affect fiscal 2026.

Recurring Revenue and Pipeline Factors to Watch

Items to follow include the pace of recurring revenue relative to device sales, NIRLab device and scan growth, and the timing of the next-generation MX908 launch. The size and timing of defense and corrections orders, which can make quarterly device sales uneven, is another variable.

Management said product placements fluctuate from period to period, so quarter-to-quarter comparisons may vary.